The effect of cimetidine on the pharmacokinetics of epirubicin in patients with advanced breast cancer: Preliminary evidence of a potentially common drug interaction

Clinical Oncology

Volumn 10, Issue 1, 1998, Pages 35-38

  Murray, L S ^a   Jodrell, D I ^b   Morrison, J G ^c   Cook, A ^a   Kerr, D J ^b   Whiting, B ^a   Kaye, S B ^b   Cassidy, J ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^c BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

Author keywords

Cimetidine; Drug interaction; Epirubicin

Indexed keywords

ANTINEOPLASTIC AGENT; CIMETIDINE; CYTOCHROME P450; EPIRUBICIN; EPIRUBICINOL; HISTAMINE H2 RECEPTOR ANTAGONIST; INDOCYANINE GREEN; PREDNISOLONE;

ADVANCED CANCER; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; ENZYME INHIBITION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER; LIVER BLOOD FLOW; ORAL DRUG ADMINISTRATION; PLASMA CLEARANCE; PRIORITY JOURNAL;

EID: 0031912977     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0936-6555(98)80109-X     Document Type: Article

References (11)

1. Cersosimo RJ, Hong WK. Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. J Clin Oncol 1986;4:425-39.
2. Weenen H, Lankelma J, Penders PGM, et al. Pharmacokinetics of 4′-epi-doxorubicin in man. Invest New Drugs 1983;1:59-64.
3. Weenen H, van Maanen JMS, de Planque MM, et al. Metabolism of 4′ modified analogs of doxorubicin. Unique glucuronidation pathway for 4′-epidoxombicin. Eur J Cancer Clin Oncol 1984;20:919-26.
4. Brenner DE, Collins JC, Hande KR. The effects of cimetidine upon the plasma pharmacokinetics of doxorubicin in rabbits. Cancer Chemother Pharmacol 1986;18:219-22.
5. Bastholt L, Dalmark M, Gjedde S, et al. Dose-relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomised study of epirubicin at four different dose levels by the Danish Breast Cancer Cooperative Group. J Clin Oncol 1996;14:1146-55.
6. Gerber MC, Tejwani GA, Gerber N, et al. Drug interactions with cimetidine: an update. Clin Pharmacol Ther 1985; 27:353-70.
7. Feely J, Wilkinson JR, Wood AJJ. Reduction of liver blood flow and propranolol metabolism by cimetidine. N Engl J Med 1981;304:692-5.
8. Henry DA, MacDonald IA, Kitchingman G, et al. Cimetidine and ranitidine: comparison of effects on hepatic drug metabolism. BMJ 1980;281:775-7.
9. Robert J. Extraction of anthracyclines from biological fluids for HPLC evaluation. J Liquid Chromatogr 1980;3:1561-72.
10. Harris NL, Brenner DE, Anthony LB, et al. The influence of ranitidine on the pharmacokinetics and toxicity of doxorubicin in rabbits. Cancer Chemother Pharmacol 1988;21:323-9.
11. Jackson JE. Reduction of liver blood flow by cimetidine. N Engl J Med 1981;305:99-100.